AI-enhanced metabolic imaging: a non-invasive and precise IVF assessment tool

AI增强代谢成像：无创精准IVF评估工具

• 批准号: 10457740
• 负责人: Timothy Sanchez
• 金额: $ 25.79万
• 依托单位: OPTIVA FERTILITY, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2022-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10457740
• 关键词: Address; Affect; Age; Agreement; Aneuploidy; Area; Artificial Intelligence; Assessment tool; Biopsy; Boston; Calibration; Clinic; Clinical; Code; Color; Computer software; Couples; Data; Data Set; Development; Embryo; Embryo Transfer; Engineering; Enrollment; Feedback; Fertility; Fertilization in Vitro; Generations; Grant; Human; Image; Image Enhancement; Imaging technology; Infertility; Institutional Review Boards; Intervention Trial; Left; Light; Measures; Medical; Metabolic; Metabolism; Methods; Microscopy; Mitochondria; Modeling; Morphology; Observational Study; Participant; Pathway interactions; Patients; Phase; Pilot Projects; Play; Positioning Attribute; Pregnancy; Preimplantation Diagnosis; Preparation; Process; Quality Control; Research; Research Design; Role; Sample Size; Sampling; Services; Site; System; Techniques; Technology; Technology Assessment; Testing; Training; Work; Writing; artificial intelligence algorithm; base; blastocyst; clinical center; cost; design; detector; egg; fluorescence lifetime imaging; imaging system; improved; large datasets; metabolic imaging; metabolic profile; novel; pilot trial; prediction algorithm; prototype; success; tool

Project Summary The development of a non-invasive, objective embryo viability assessment remains an unmet need in IVF treatment. In this work, Optiva Fertility aims to develop a novel embryo assessment based on metabolic imaging using Fluorescence Lifetime Imaging (FLIM) in conjunction with artificial intelligence (AI) techniques. To date, Optiva Fertility has designed, tested, and deployed a first generation metabolic imaging system and has commenced clinical work. Bringing this technology to the point where it provides significant benefit to IVF patients requires a multi-stage development and verification process which forms the basis for the proposed work in this grant. Based on the results from an observational pilot trial, Optiva will design a large scale, multi-site observational trial. The purpose of this study is to obtain a dataset large enough to train robust AI models for assessing embryo viability. Facilitating this trial will require engineering and constructing a second generation metabolic imaging system featuring a more compact and integrated hardware design, automated calibration, upgraded controls software, and enhanced imaging technology. It is anticipated that this system will be very similar to the eventual commercial product. Successful completion of this work will further the understanding of the role metabolism plays in embryo viability, as well as leave Optiva well positioned to undertake a pivotal interventional trial.

项目摘要 开发一种非侵入性的、客观的胚胎存活评估方法仍然是一个未完成的任务。 需要进行体外受精治疗。在这项工作中，Optiva生育公司旨在开发一种新的胚胎评估 基于结合使用荧光寿命成像(FLIM)的代谢成像 人工智能(AI)技术。到目前为止，Optiva Fertility已经设计、测试和部署了 第一代代谢成像系统，并已开始临床工作。 将这项技术带到为试管受精患者提供显著好处的程度需要 构成拟议工作基础的多阶段开发和验证过程 在这笔赠款中。基于观察性试点试验的结果，Optiva将设计一种大型 规模、多点观察性试验。本研究的目的是获得足够大的数据集 训练健壮的人工智能模型以评估胚胎的存活能力。协助这项试验将需要 设计和构建第二代代谢成像系统，具有更多 紧凑和集成的硬件设计、自动校准、升级的控制软件、 和增强的成像技术。预计该系统将非常类似于 最终的商业产品。这项工作的圆满完成将进一步加深对 新陈代谢在胚胎存活中的作用，以及使Optiva处于有利地位 进行一项关键的介入试验。